FTSE MIB
34.151,13 -576,27 (-1,66%) Dow Jones
42.313,00 +137,90 (+0,33%) Nasdaq
18.119,59 -70,71 (-0,39%) Nikkei 225
37.919,55 -1.910,01 (-4,80%) Petrolio
68,24 +0,06 (+0,09%) Bitcoin EUR
56.849,71 -1.733,38 (-2,96%)
TGTX Jan 2025 1.000 call
- GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy. A link to the presentation is included below. Michael S. Weiss, Chairman and Chief Executive Officer of
- GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy. Abstr
